MabVax Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017
MabVax Therapeutics Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $5,092,314 compared to $4,204,295 a year ago. Net loss allocable to common stockholders was $5,354,854 or $0.85 per basic and diluted share compared to $4,404,770 or $1.12 per basic and diluted share a year ago.